Cargando…
Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach
Secreted alpha-toxin and surface-localized clumping factor A (ClfA) are key virulence determinants in Staphylococcus aureus bloodstream infections. We previously demonstrated that prophylaxis with a multimechanistic monoclonal antibody (MAb) combination against alpha-toxin (MEDI4893*) and ClfA (11H1...
Autores principales: | Tkaczyk, C., Kasturirangan, S., Minola, A., Jones-Nelson, O., Gunter, V., Shi, Y. Y., Rosenthal, K., Aleti, V., Semenova, E., Warrener, P., Tabor, D., Stover, C. K., Corti, D., Rainey, G., Sellman, B. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527613/ https://www.ncbi.nlm.nih.gov/pubmed/28584141 http://dx.doi.org/10.1128/AAC.00629-17 |
Ejemplares similares
-
Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity In Vitro and Staphylococcus aureus Fitness in Infection Models
por: Tkaczyk, C., et al.
Publicado: (2018) -
Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease
por: Tkaczyk, C., et al.
Publicado: (2016) -
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6
por: Moshoette, Tumelo, et al.
Publicado: (2022) -
Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
por: Surowka, Marlena, et al.
Publicado: (2021) -
Antibacterial Monoclonal Antibodies Do Not Disrupt the Intestinal Microbiome or Its Function
por: Jones-Nelson, Omari, et al.
Publicado: (2020)